Developer docs
API playgroundTry for free, no card

Search company profiles

vTv Therapeutics

Full company profile

uuid000254n

Namestring
vTv Therapeutics
Legal namestring
vTv Therapeutics Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

vTv Therapeutics is a late-stage clinical biopharmaceutical company headquartered in High Point, North Carolina, that develops oral small-molecule drug candidates for diabetes and related chronic diseases. The company's lead asset is cadisegliatin (TTP399), a liver-selective glucokinase activator (GKA) designed to restore the liver's natural role in glucose storage and release; it is being investigated as the first potential oral adjunctive therapy to insulin for people with Type 1 diabetes (T1D), a population of approximately 1.5 million Americans where roughly 75% do not maintain the American Diabetes Association's HbA1c target of less than 7%. Cadisegliatin received FDA Breakthrough Therapy designation in April 2021 and is currently enrolling the Phase 3 CATT1 trial, with enrollment targeted for Q3 2026 and topline data expected in the first half of 2027. Supporting pipeline assets include TTP273, an Nrf2/Bach1 modulator program, the PPAR-delta agonist HPP593 (Mavodelpar), and HPP737, a PDE4 inhibitor whose global rights were licensed to Newsoara Biopharma in February 2026 for $20 million upfront plus up to $115 million in milestones and tiered royalties.

Short descriptiontext

vTv Therapeutics is a late-stage clinical biopharmaceutical company developing cadisegliatin (TTP399), an oral liver-selective glucokinase activator in Phase 3 development as the first potential oral adjunctive therapy to insulin for Type 1 diabetes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHigh Point, United States
HQ citystring
High Point
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diabetes therapeutics, small molecule drugs, glucokinase activators, biopharmaceutical development, prescription pharmaceuticals
Industry1 code
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Diabetes Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales (Future)
TypeOne Time License
Description

Revenue from commercializing cadisegliatin and other drug candidates upon regulatory approval. As a late-stage biopharmaceutical company, vTv's primary future revenue stream would be product sales of prescription pharmaceuticals distributed through pharmacy channels.

biospace.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue from licensing agreements including upfront payments, development milestones, and sales milestones. The company received $20 million upfront from Newsoara for HPP737 global rights, with potential additional milestones of up to $115 million. Previous licensing deals included $25 million from G42 Healthcare and $10 million from CinPax.

biospace.com
3Royalties on Net Sales
TypeLicensing Royalties
Description

Ongoing royalty payments based on net sales of licensed products. The HPP737 license agreement includes tiered royalties on future sales.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

vTv Therapeutics is a late-stage biopharmaceutical company developing oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), an oral liver-selective glucokinase activator currently in a Phase 3 trial as a potential first-in-class adjunctive therapy to insulin for Type 1 diabetes. The company also develops HPP737 (a PDE4 inhibitor licensed to Newsoara), TTP273, an Nrf2/Bach1 program, and a PPAR-delta agonist.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 0.3% statistically significant reduction in HbA1c (p=0.0017) in 12-week SimpliciT1 Phase 2 trial (n=81)
+4 more records
Product overview1 text field

vTv Therapeutics is a late-stage biopharmaceutical company developing a portfolio of oral small-molecule drug candidates for diabetes and related chronic diseases. The company's clinical pipeline is led by cadisegliatin (TTP399), an oral liver-selective glucokinase activator in Phase 3 development as an adjunctive therapy to insulin for type 1 diabetes. Supporting candidates include TTP273, Nrf2/Bach1 Program, TTP-RA, and PPAR-δ (HPP593/MAVODELPAR). HPP737, a PDE4 inhibitor, has been licensed to Newsoara Biopharma for global development and commercialization. The company operates as a single-focus pharmaceutical developer rather than a platform-based product company.

Product and service2 records
1Cadisegliatin (TTP399)
CategoryDiabetes prescription pharmaceutical (lead pipeline product)
Description

Oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin for the treatment of Type 1 diabetes; currently in the Phase 3 CATT1 trial with FDA Breakthrough Therapy designation and potential to become the first FDA-approved oral adjunctive therapy to insulin.

2HPP737 (PDE4 inhibitor)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Newsoara Biopharma Co. Ltd.
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-02-01
Description

Expanded license agreement granting Newsoara Biopharma exclusive worldwide rights to develop and commercialize the PDE4 inhibitor HPP737. vTv received a $20 million upfront payment in February 2026, with potential development milestones of up to $50 million, sales milestones of up to $65 million, and tiered royalties on net sales. The prior regional license agreement (May 2018) had become void in June 2025, and this amendment establishes a global collaboration.

biospace.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Collaboration with M42's IROS to conduct a Phase 2 clinical trial evaluating cadisegliatin as adjunctive therapy to insulin for Type 2 diabetes. The trial will enroll approximately 300 patients across the UAE, Jordan, and Tunisia, with first patient visit expected in Q1 2026. Under the collaboration, vTv serves as regulatory sponsor while M42 funds the study.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing peptide-based therapeutics for diabetes and metabolic diseases, sharing similar development-stage dynamics, public-company status, and therapeutic area focus.

TypeBroad incumbent
Description

Global leader in insulin therapy (NovoLog, Levemir, Tresiba, Fiasp) and diabetes care, setting the standard of care that cadisegliatin would complement as adjunctive therapy if approved.

TypeEmerging player
Description

Omnipod tubeless insulin pump and AID system provider, competing in T1D management through device innovation that could reduce demand for pharmacological adjuncts over time.

TypeEmerging player
Description

Leading continuous glucose monitor manufacturer whose G6/G7 technology addresses T1D glycemic control and hypoglycemia without pharmacology, representing a non-pharmacological competitive approach in the same patient population.

TypeBroad incumbent
Description

Major diabetes player with established insulin portfolio (Lantus, Toujeo) and acquired Provention Bio's T1D asset teplizumab (Tzield), positioning the company as both broad incumbent and direct T1D competitor.

TypeBroad incumbent
Description

Major diabetes incumbent with leading insulin franchise (Humalog, Humulin, Lyumjev) and incretin therapies (Mounjaro, Trulicity), representing the dominant competitive backdrop and standard of care for any new T1D therapeutic.

TypeDirect peer
Description

Public biopharmaceutical company focused on diabetes therapeutics with commercialized inhaled insulin (Afrezza) and endocrine pipeline, directly comparable in therapeutic area and stage of commercialization.

TypeDirect peer
Description

Was a T1D-focused biopharmaceutical company developing teplizumab (Tzield) for Type 1 diabetes, acquired by Sanofi in 2023. Highly comparable in T1D focus and late-stage development prior to acquisition.

TypeDirect peer
Description

Late-stage clinical biopharmaceutical company developing small-molecule drug candidates for diabetes and other metabolic diseases, with comparable market cap profile and clinical-stage business model focused on oral therapies.

TypeEmerging player
Description

Insulin pump and automated insulin delivery system manufacturer (t:slim X2, Control-IQ) offering device-based solutions for T1D management, addressing the same patient population via alternative modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

vTv Therapeutics

Diabetes Biopharmaceuticalsvtvtherapeutics.com

vTv Therapeutics is a late-stage clinical biopharmaceutical company developing cadisegliatin (TTP399), an oral liver-selective glucokinase activator in Phase 3 development as the first potential oral adjunctive therapy to insulin for Type 1 diabetes.

What vTv Therapeutics does

vTv Therapeutics is a late-stage clinical biopharmaceutical company headquartered in High Point, North Carolina, that develops oral small-molecule drug candidates for diabetes and related chronic diseases. The company's lead asset is cadisegliatin (TTP399), a liver-selective glucokinase activator (GKA) designed to restore the liver's natural role in glucose storage and release; it is being investigated as the first potential oral adjunctive therapy to insulin for people with Type 1 diabetes (T1D), a population of approximately 1.5 million Americans where roughly 75% do not maintain the American Diabetes Association's HbA1c target of less than 7%. Cadisegliatin received FDA Breakthrough Therapy designation in April 2021 and is currently enrolling the Phase 3 CATT1 trial, with enrollment targeted for Q3 2026 and topline data expected in the first half of 2027. Supporting pipeline assets include TTP273, an Nrf2/Bach1 modulator program, the PPAR-delta agonist HPP593 (Mavodelpar), and HPP737, a PDE4 inhibitor whose global rights were licensed to Newsoara Biopharma in February 2026 for $20 million upfront plus up to $115 million in milestones and tiered royalties.

vTv Therapeutics firmographics

Firmographics
Name
vTv Therapeutics
Legal name
vTv Therapeutics Inc.
Website
https://vtvtherapeutics.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
vTv Therapeutics is a late-stage clinical biopharmaceutical company developing cadisegliatin (TTP399), an oral liver-selective glucokinase activator in Phase 3 development as the first potential oral adjunctive therapy to insulin for Type 1 diabetes.
Ownership category
akta.pro rank

vTv Therapeutics industry classification

Industry
Product category
Diabetes Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Diabetes therapeutics
  • Small molecule drugs
  • Glucokinase activators
  • Biopharmaceutical development
  • Prescription pharmaceuticals

Where vTv Therapeutics is headquartered

Location

Headquarters

HQ city
High Point
HQ country
United States
HQ region
North America

Offices1 record

Markets served

vTv Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales (Future): Revenue from commercializing cadisegliatin and other drug candidates upon regulatory approval. As a late-stage biopharmaceutical company, vTv's primary future revenue stream would be product sales of prescription pharmaceuticals distributed through pharmacy channels.
  2. Licensing and Milestone Payments: Revenue from licensing agreements including upfront payments, development milestones, and sales milestones. The company received $20 million upfront from Newsoara for HPP737 global rights, with potential additional milestones of up to $115 million. Previous licensing deals included $25 million from G42 Healthcare and $10 million from CinPax.
  3. Royalties on Net Sales: Ongoing royalty payments based on net sales of licensed products. The HPP737 license agreement includes tiered royalties on future sales.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

vTv Therapeutics product offering

Product offering

Core offering

vTv Therapeutics is a late-stage biopharmaceutical company developing oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), an oral liver-selective glucokinase activator currently in a Phase 3 trial as a potential first-in-class adjunctive therapy to insulin for Type 1 diabetes. The company also develops HPP737 (a PDE4 inhibitor licensed to Newsoara), TTP273, an Nrf2/Bach1 program, and a PPAR-delta agonist.

Product overview

vTv Therapeutics is a late-stage biopharmaceutical company developing a portfolio of oral small-molecule drug candidates for diabetes and related chronic diseases. The company's clinical pipeline is led by cadisegliatin (TTP399), an oral liver-selective glucokinase activator in Phase 3 development as an adjunctive therapy to insulin for type 1 diabetes. Supporting candidates include TTP273, Nrf2/Bach1 Program, TTP-RA, and PPAR-δ (HPP593/MAVODELPAR). HPP737, a PDE4 inhibitor, has been licensed to Newsoara Biopharma for global development and commercialization. The company operates as a single-focus pharmaceutical developer rather than a platform-based product company.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cadisegliatin (TTP399) Oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin for the treatment of Type 1 diabetes; currently in the Phase 3 CATT1 trial with FDA Breakthrough Therapy designation and potential to become the first FDA-approved oral adjunctive therapy to insulin.
  • HPP737 (PDE4 inhibitor)

Quantifiable outcome

  • 0.3% statistically significant reduction in HbA1c (p=0.0017) in 12-week SimpliciT1 Phase 2 trial (n=81)
  • +4 more outcomes

Companies that use vTv Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

vTv Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

vTv Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Newsoara Biopharma Co. Ltd.coreOEM/ Whitelabel/ Licensing Partner · 1 February 2026Expanded license agreement granting Newsoara Biopharma exclusive worldwide rights to develop and commercialize the PDE4 inhibitor HPP737. vTv received a $20 million upfront payment in February 2026, with potential development milestones of up to $50 million, sales milestones of up to $65 million, and tiered royalties on net sales. The prior regional license agreement (May 2018) had become void in June 2025, and this amendment establishes a global collaboration.
  • M42's Insights Research Organization & Solutions (IROS)coreStrategic or Co-development Partner · 18 December 2025Collaboration with M42's IROS to conduct a Phase 2 clinical trial evaluating cadisegliatin as adjunctive therapy to insulin for Type 2 diabetes. The trial will enroll approximately 300 patients across the UAE, Jordan, and Tunisia, with first patient visit expected in Q1 2026. Under the collaboration, vTv serves as regulatory sponsor while M42 funds the study.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

vTv Therapeutics competitors and assessment

Company assessment

Direct peers

  • Zealand Pharma: Clinical-stage biopharmaceutical company developing peptide-based therapeutics for diabetes and metabolic diseases, sharing similar development-stage dynamics, public-company status, and therapeutic area focus.
  • MannKind Corporation: Public biopharmaceutical company focused on diabetes therapeutics with commercialized inhaled insulin (Afrezza) and endocrine pipeline, directly comparable in therapeutic area and stage of commercialization.
  • Provention Bio: Was a T1D-focused biopharmaceutical company developing teplizumab (Tzield) for Type 1 diabetes, acquired by Sanofi in 2023. Highly comparable in T1D focus and late-stage development prior to acquisition.
  • Lexicon Pharmaceuticals: Late-stage clinical biopharmaceutical company developing small-molecule drug candidates for diabetes and other metabolic diseases, with comparable market cap profile and clinical-stage business model focused on oral therapies.

Broad incumbents

  • Novo Nordisk: Global leader in insulin therapy (NovoLog, Levemir, Tresiba, Fiasp) and diabetes care, setting the standard of care that cadisegliatin would complement as adjunctive therapy if approved.
  • Sanofi: Major diabetes player with established insulin portfolio (Lantus, Toujeo) and acquired Provention Bio's T1D asset teplizumab (Tzield), positioning the company as both broad incumbent and direct T1D competitor.
  • Eli Lilly and Company: Major diabetes incumbent with leading insulin franchise (Humalog, Humulin, Lyumjev) and incretin therapies (Mounjaro, Trulicity), representing the dominant competitive backdrop and standard of care for any new T1D therapeutic.

Emerging players

  • Insulet Corporation: Omnipod tubeless insulin pump and AID system provider, competing in T1D management through device innovation that could reduce demand for pharmacological adjuncts over time.
  • Dexcom: Leading continuous glucose monitor manufacturer whose G6/G7 technology addresses T1D glycemic control and hypoglycemia without pharmacology, representing a non-pharmacological competitive approach in the same patient population.
  • Tandem Diabetes Care: Insulin pump and automated insulin delivery system manufacturer (t:slim X2, Control-IQ) offering device-based solutions for T1D management, addressing the same patient population via alternative modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

vTv Therapeutics social profiles

Digital presence

vTv Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

vTv Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

vTv Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

vTv Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

vTv Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about vTv Therapeutics

What does vTv Therapeutics do?

vTv Therapeutics is a late-stage biopharmaceutical company developing oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), an oral liver-selective glucokinase activator currently in a Phase 3 trial as a potential first-in-class adjunctive therapy to insulin for Type 1 diabetes. The company also develops HPP737 (a PDE4 inhibitor licensed to Newsoara), TTP273, an Nrf2/Bach1 program, and a PPAR-delta agonist.

Is vTv Therapeutics a public or private company?

vTv Therapeutics is a public company. It is classified as public and is currently operating.

When was vTv Therapeutics founded?

vTv Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is vTv Therapeutics based?

vTv Therapeutics is headquartered in High Point, United States, in the North America region.

How does vTv Therapeutics make money?

Three revenue lines are on record. Pharmaceutical Product Sales (Future) is the primary driver. The others are licensing and Milestone Payments and royalties on Net Sales.

Who are vTv Therapeutics's main competitors?

Direct peers on record are Zealand Pharma, MannKind Corporation, Provention Bio and Lexicon Pharmaceuticals. Broad incumbents are Novo Nordisk, Sanofi and Eli Lilly and Company. Emerging players are Insulet Corporation, Dexcom and Tandem Diabetes Care.

Does vTv Therapeutics have an API?

No public API is recorded for vTv Therapeutics.

What industry is vTv Therapeutics in?

vTv Therapeutics's product category is Diabetes Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsComparing vTv Therapeutics (VTVT) and Its RivalsvTv Therapeutics is compared to pharmaceutical peers on profitability, valuation, and analyst ratings. It trades at a lower P/E ratio and has a consensus price target of $55.83, implying 165.49% upside. The company beats peers on 8 of 13 factors.American Banking and Market NewsvTv Therapeutics (VTVT) Projected to Post Earnings on ThursdayvTv Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $1.07 per share and revenue of $0.33 million. The company's stock opened at $23.55, and analysts have a consensus rating of Moderate Buy with an average target price of $55.83.MarketBeatvTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Consensus Price Target of $55.83Analysts rate vTv Therapeutics a Moderate Buy with an average 12-month price target of $55.83. China Universal Asset Management raised its stake by 114.4% in Q3, and the stock opened at $25.17. The company reported a loss of $1.05 per share, missing estimates.American Banking and Market NewsvTv Therapeutics Inc. (VTVT) – What Are Investment Firms Thinking About This Stock?Analysts rate vTv Therapeutics a Moderate Buy with an average price target of $55.83. The stock opened at $25.17, and China Universal Asset Management increased its stake by 114.4% in Q3. The company reported a loss of $1.05 per share for the quarter.MarketBeatvTv Therapeutics (VTVT) Expected to Release Quarterly Earnings on ThursdayvTv Therapeutics is expected to release Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $1.07 per share and revenue of $0.33 million. The company's stock opened at $25.72, and analysts have a consensus rating of Moderate Buy with an average target price of $55.83.Markets DailyvTv Therapeutics (NASDAQ:VTVT) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded vTv Therapeutics from a hold to a sell rating. The stock has a consensus rating of Moderate Buy with an average target price of $55.83. The company reported a loss of $1.05 per share for the quarter, missing estimates.MarketBeatvTv Therapeutics (NASDAQ:VTVT) Stock Bumped Down to Sell by Wall Street ZenWall Street Zen downgraded vTv Therapeutics from hold to sell, while other analysts issued mixed ratings. The stock opened at $25.55, down 5.9%, with a consensus target of $55.83. The company reported a loss of $1.05 per share, missing estimates.Seeking AlphavTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program TranscriptvTv Therapeutics held a KOL event on October 20, 2026, discussing hypoglycemia burden in type 1 diabetes and its cadisegliatin Phase 3 program. CEO Paul Sekhri opened the call, noting hypoglycemia remains a persistent burden beyond individual episodes. The presentation included forward-looking statements about the company's plans.Ticker ReportvTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 HypoglycemiavTv Therapeutics highlighted its Phase III CATT1 trial for cadisegliatin, an oral glucokinase activator for type 1 diabetes, with top-line results expected in mid-2027. The company cited survey data showing 65% of patients reported hypoglycemia-related burden, and cadisegliatin has received FDA Breakthrough Therapy designation.MarketBeatvTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 HypoglycemiavTv Therapeutics held a virtual event to discuss cadisegliatin's Phase III CATT1 trial for type 1 diabetes hypoglycemia. The trial, with 166 participants, aims to show a 30% reduction in hypoglycemia, with top-line results expected in mid-2027. The company has $86.6 million in cash and FDA Breakthrough Therapy designation.